Anxiolytic activity of the neuroprotective peptide HLDF-6 and its effects on brain neurotransmitter systems in BALB/c and C57BL/6 mice.

This study is focused on a new amide derivative of the peptide HLDF-6 (Thr-Gly-Glu-Asn-His-Arg). This hexapeptide is a fragment of Human Leukaemia Differentiation Factor (HLDF). It displays a broad range of nootropic and neuroprotective activities.

Cortical and hippocampal EEG effects of neurotransmitter agonists in spontaneously hypertensive vs. kainate-treated rats.

To analyze mediatory mechanisms underlying attention-deficit hyperactivity disorder (ADHD) and their association with epilepsy, the electroencephalogram (EEG) responses to various centrally applied neurotransmitter agonists were studied in spontaneously hypertensive (SH), kainate-treated (KA), and normotensive (control) rats, with chronically implanted electrodes into the frontal cortex and hippocampus and a cannula into the lateral cerebral ventricle. In SH rats, the baseline EEG showed increased delta and beta2 activity in the hippocampus and decreased alpha/beta1 activity in both brain areas. In KA rats, these delta and alpha/beta1 effects were observed 2 weeks post-kainate, while the beta2 activity increase occurred after 5 weeks in the hippocampus and, to a greater extent, 9 weeks post-injection in both brain areas.

Effects of neurotransmitter agonists on electrocortical activity in the rat kainate model of temporal lobe epilepsy and the modulatory action of basic fibroblast growth factor.

We used systemic kainic acid (KA) injection to investigate how the development of temporal lobe epilepsy and the associated network reorganization affect the electrocorticogram (ECoG) responses to various neurotransmitter agonists. Unrestrained rats chronically implanted with electrodes over somatosensory cortex and dorsal hippocampus and a cannula into the right lateral ventricle were used to investigate the ECoG frequency responses of intracerebroventricularly applied agonists (NMDA, clonidine, muscimol, and baclofen) at several types of receptors [NMDA, alpha2-adrenergic (NE), GABAA, and GABAB, respectively] in KA-treated versus naïve animals. The ECoG was analyzed 2, 5, and 9 weeks after intraperitoneal injection of KA alone or in combination with basic fibroblast growth factor (bFGF, intracerebroventricularly).